| |
Provision of HIV pre-exposure prophylaxis to female patients seeking family planning services in the United States
|
| |
| |
Download the PDF here
AIDS: September 22, 2022 Satish, Sanjanaa; Bravo, Liciab; McAllister, Ardenc; Teitelman, Anned; Sonalkar, Saritac
Abstract
Objective:
We conducted a scoping review to assess barriers to and facilitators of integrating HIV pre-exposure prophylaxis (PrEP) and family planning (FP) at the patient, provider, and implementation levels, and to identify gaps in knowledge.
Methods:
We conducted a search of five bibliographic databases from database inception to March 2022: PubMed, CINAHL, Embase, Web of Science and Scopus. Two reviewers screened abstracts and full texts to determine eligibility based on a priori inclusion and exclusion criteria. We categorized studies by their relevance to patient, provider, and implementation barriers, and extracted data based on pre-specified elements.
Results:
Our initial search strategy yielded 1151 results, and 34 publications were included. Barriers to PrEP implementation in family planning settings included low PrEP knowledge among patients, hesitance to take PrEP due to perceived stigma, decreased willingness of providers unfamiliar with PrEP to prescribe PrEP, and limited financial and staffing resources that make prescribing and monitoring PrEP difficult. Facilitators included robust training for providers, stigma reduction efforts, leadership engagement, and increased resources specifically in settings with processes in place that ease the process of prescribing and monitoring PrEP.
Conclusions:
Advances in implementation strategy development, stigma reduction, and drug development will be essential to reinforcing PrEP care in family planning settings and thereby reducing the incidence of HIV in women through highly effective pharmacologic HIV prevention methods.
|
|
| |
| |
|
|
|
